Flexion Therapeutics, Inc. (FLXN)
| Market Cap | 309.80M |
| Revenue (ttm) | 102.74M |
| Net Income (ttm) | -95.05M |
| Shares Out | 49.97M |
| EPS (ttm) | -1.92 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,359,064 |
| Open | 6.07 |
| Previous Close | 6.23 |
| Day's Range | 5.88 - 6.22 |
| 52-Week Range | 4.30 - 13.66 |
| Beta | 1.34 |
| Analysts | Buy |
| Price Target | 18.00 (+194.6%) |
| Est. Earnings Date | Nov 3, 2021 |
About FLXN
Flexion Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for the treatment of patients with musculoskeletal conditions in the United States. The company offers ZILRETTA, an intra-articular injection for the management of osteoarthritis (OA) knee pain. It is also involved in the development of FX201, a gene therapy product candidate designed to provide on demand production of an anti-inflammatory protein, interleukin-1 receptor antagonist for pain relief from OA of the kne...
Financial Performance
In 2020, FLXN's revenue was $85.55 million, an increase of 17.26% compared to the previous year's $72.96 million. Losses were -$113.71 million, -24.08% less than in 2019.
Financial StatementsAnalyst Forecast
According to 11 analysts, the average rating for FLXN stock is "Buy." The 12-month stock price forecast is 18.00, which is an increase of 194.60% from the latest price.
News
Flexion Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
BURLINGTON, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in a vi...
Flexion Therapeutics to Present at the Wells Fargo 2021 Virtual Healthcare Conference
BURLINGTON, Mass., Sept. 03, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an a...
Flexion Therapeutics Announces Inclusion of ZILRETTA® in American Academy of Orthopaedic Surgeons (AAOS) Clinical Pra...
BURLINGTON, Mass., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced that the American Academy of Orthopaedic Surgeons (AAOS) included ZILRETTA (triamcinolone acetoni...
Flexion Therapeutics (FLXN) Upgraded to Buy: Here's What You Should Know
Flexion Therapeutics (FLXN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Why Is Flexion Therapeutics (FLXN) Stock Gaining On Wednesday?
Flexion Therapeutics Inc (NASDAQ: FLXN) expanded the Phase 1b trial of FX301 in patients undergoing bunionectomy. Related: Flexion Therapeutics To Start Testing FX301 For Post-Op Pain In Patients Aft...
Flexion Therapeutics Announces Expansion of Phase 1b Trial Investigating FX301 for the Management of Post-Operative Pain
BURLINGTON, Mass., Aug. 25, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced the expansion of the Phase 1b randomized, double-blind, placebo-controlled trial of FX301 in...
Why Flexion Therapeutics (FLXN) Could Be an Impressive Growth Stock
If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Flexion Therapeutics (FLXN).
Down 24.7% in 4 Weeks, Here's Why You Should You Buy the Dip in Flexion Therapeutics (FLXN)
The heavy selling pressure might have exhausted for Flexion Therapeutics (FLXN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street ...
Flexion Therapeutics Announces Publication of Results from Phase 2 Pharmacokinetics (PK) and Safety Study of ZILRETTA...
BURLINGTON, Mass., Aug. 09, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced that the results from the randomized, open-label, Phase 2 pharmacokinetic (PK) trial of ZILRETTA (...
Flexion Therapeutics (FLXN) Reports Q2 Loss, Tops Revenue Estimates
Flexion Therapeutics (FLXN) delivered earnings and revenue surprises of 12.00% and 0.56%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Flexion Therapeutics Reports Second-Quarter 2021 Financial Results and Recent Business Highlights
BURLINGTON, Mass., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today reported financial results and recent business highlights for the quarter ended June 30, 2021.
Flexion Therapeutics to Report Second-Quarter 2021 Financial Results on August 4, 2021
BURLINGTON, Mass., July 29, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report its second-quarter 2021 financial results after the close of the U.S. fi...
Flexion Therapeutics (FLXN) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
Flexion Therapeutics (FLXN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Flexion Therapeutics Announces Appointment of Utpal Koppikar to its Board of Directors
BURLINGTON, Mass., July 12, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced the appointment of Utpal Koppikar, Chief Financial Officer of Atara Biotherapeutics, to its ...
Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BURLINGTON, Mass., July 02, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to five new employees consisting of 20,440 restricted stock units. ...
4 Biotech and Life Sciences Stocks Trading Under $10 With Gigantic Upside Potential
While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.
Flexion Therapeutics to Present at the 2021 Raymond James Human Health Innovation Conference
BURLINGTON, Mass., June 14, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an an...
Flexion Therapeutics Announces Appointment of William T. Andrews, M.D.
BURLINGTON, Mass., June 09, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that William T. Andrews, M.D., F.A.C.P., will join the company as Chief Medical Officer (CMO...
Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BURLINGTON, Mass., June 04, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to five new employees consisting of 8,510 restricted stock units. T...
New Strong Sell Stocks for June 4th
ASLN, BLRX, FLXN, ICMB, and MRNS have been added to the Zacks Rank #5 (Strong Sell) List on June 4, 2021.
Flexion Therapeutics to Present at the Goldman Sachs 42nd Annual Global Healthcare Virtual Conference
BURLINGTON, Mass., June 02, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an an...
Flexion Therapeutics to Present at the RBC Capital Markets 2021 Virtual Global Healthcare Conference
BURLINGTON, Mass., May 13, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an ana...
Flexion Therapeutics: Q1 Earnings Insights
Shares of Flexion Therapeutics (NASDAQ:FLXN) rose in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share rose 40.00% year over year to ($0.57), which missed ...
Flexion Therapeutics Reports First-Quarter 2021 Financial Results and Recent Business Updates
BURLINGTON, Mass., May 12, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today reported financial results and recent business highlights for the quarter ended March 31, 2021.